KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Jazz Pharmaceuticals (JAZZ) EBITDA (2016 - 2025)

Jazz Pharmaceuticals has reported EBITDA over the past 16 years, most recently at $254.5 million for Q4 2025.

  • Quarterly EBITDA rose 33.43% to $254.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$304.8 million through Dec 2025, down 151.18% year-over-year, with the annual reading at -$430.2 million for FY2025, 160.04% down from the prior year.
  • EBITDA was $254.5 million for Q4 2025 at Jazz Pharmaceuticals, up from $57.5 million in the prior quarter.
  • Over five years, EBITDA peaked at $260.2 million in Q3 2024 and troughed at -$686.4 million in Q2 2025.
  • The 5-year median for EBITDA is $86.5 million (2022), against an average of $48.7 million.
  • Biggest five-year swings in EBITDA: tumbled 633.39% in 2022 and later surged 596.17% in 2023.
  • Tracing JAZZ's EBITDA over 5 years: stood at $49.4 million in 2021, then tumbled by 633.39% to -$263.4 million in 2022, then surged by 146.51% to $122.5 million in 2023, then soared by 55.73% to $190.8 million in 2024, then skyrocketed by 33.43% to $254.5 million in 2025.
  • According to Business Quant data, EBITDA over the past three periods came in at $254.5 million, $57.5 million, and -$686.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.